Literature DB >> 33716930

Levetiracetam and N-Cadherin Antibody Alleviate Brain Pathology Without Reducing Early Epilepsy Development After Focal Non-convulsive Status Epilepticus in Rats.

Una Avdic1,2, Matilda Ahl1,2, My Andersson1,2, Christine T Ekdahl1,2.   

Abstract

Focal non-convulsive status epilepticus (fNCSE) is a neurological condition characterized by a prolonged seizure that may lead to the development of epilepsy. Emerging experimental evidence implicates neuronal death, microglial activation and alterations in the excitatory and inhibitory synaptic balance as key features in the pathophysiology following fNCSE. We have previously reported alterations in the excitatory adhesion molecule N-cadherin in rats with fNCSE originating from the hippocampus that subsequently also develop spontaneous seizures. In this study, fNCSE rats were treated intraperitoneally with the conventional anti-epileptic drug levetiracetam in combination with intraparenchymal infusion of N-cadherin antibodies (Ab) for 4 weeks post-fNCSE. The N-cadherin Ab was infused into the fornix and immunohistochemically N-cadherin Ab-stained neurons were detected within the dorsal hippocampal structures as well as in superjacent somatosensory cortex. Continuous levetiracetam treatment for 4 weeks post-fNCSE reduced microglia activation, including cell numbers and morphological changes, partly decreased neuronal cell loss, and excitatory post-synaptic scaffold protein PSD-95 expression in selective hippocampal structures. The additional treatment with N-cadherin Ab did not reverse neuronal loss, but moderately reduced microglial activation, and further reduced PSD-95 levels in the dentate hilus of the hippocampus. Despite the effects on brain pathology within the epileptic focus, neither monotherapy with systemic levetiracetam nor levetiracetam in combination with local N-cadherin Ab administration, reduced the amount of focal or focal evolving into bilateral convulsive seizures, seizure duration, or interictal epileptiform activity during 1 month of continuous electroenephalogram recordings within the hippocampus after fNCSE. Behavioral tests for spatial memory, anxiety, social interaction and anhedonia did not detect gross behavioral differences between fNCSE rats with or without treatment. The results reveal the refractory features of the present rodent model of temporal lobe epilepsy following fNCSE, which supports its clinical value for further therapeutic studies. We identify the persistent development of epilepsy following fNCSE, in spite of partly reduced brain pathology within the epileptic focus.
Copyright © 2021 Avdic, Ahl, Andersson and Ekdahl.

Entities:  

Keywords:  N-cadherin antibody; antiepileptic drugs; epilepsy; levetiracetam; non-convulsive status epilepticus; seizures; synaptic proteins

Year:  2021        PMID: 33716930      PMCID: PMC7943745          DOI: 10.3389/fneur.2021.630154

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  59 in total

1.  PSD-95 regulates synaptic transmission and plasticity in rat cerebral cortex.

Authors:  Jean-Claude Béïque; Rodrigo Andrade
Journal:  J Physiol       Date:  2003-02-01       Impact factor: 5.182

2.  Long-term behavioral and morphological consequences of nonconvulsive status epilepticus in rats.

Authors:  Pavel Krsek; Anna Mikulecká; Rastislav Druga; Hana Kubová; Zdenek Hlinák; Lucie Suchomelová; Pavel Mares
Journal:  Epilepsy Behav       Date:  2004-04       Impact factor: 2.937

Review 3.  The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory.

Authors:  Robert N Hughes
Journal:  Neurosci Biobehav Rev       Date:  2004-09       Impact factor: 8.989

4.  N-cadherin regulates molecular organization of excitatory and inhibitory synaptic circuits in adult hippocampus in vivo.

Authors:  Deanna L Benson; George W Huntley; Jessica S Nikitczuk; Shekhar B Patil; Bridget A Matikainen-Ankney; Joseph Scarpa; Matthew L Shapiro
Journal:  Hippocampus       Date:  2014-04-29       Impact factor: 3.899

5.  Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin.

Authors:  Paul R Lee; Dana L Brady; Robert A Shapiro; Daniel M Dorsa; James I Koenig
Journal:  Neuropsychopharmacology       Date:  2005-10       Impact factor: 7.853

6.  Role of fractalkine-CX3CR1 pathway in seizure-induced microglial activation, neurodegeneration, and neuroblast production in the adult rat brain.

Authors:  Idrish Ali; Deepti Chugh; Christine T Ekdahl
Journal:  Neurobiol Dis       Date:  2014-11-21       Impact factor: 5.996

Review 7.  Chronic epilepsy and cognition.

Authors:  Christian E Elger; Christoph Helmstaedter; Martin Kurthen
Journal:  Lancet Neurol       Date:  2004-11       Impact factor: 44.182

8.  Levetiracetam and partial seizure subtypes: pooled data from three randomized, placebo-controlled trials.

Authors:  Ilo E Leppik; Victor Biton; Josemir W A Sander; Heinz Gregor Wieser
Journal:  Epilepsia       Date:  2003-12       Impact factor: 5.864

9.  Increased numbers of coassembled PSD-95 to NMDA-receptor subunits NR2B and NR1 in human epileptic cortical dysplasia.

Authors:  Zhong Ying; William Bingaman; Imad M Najm
Journal:  Epilepsia       Date:  2004-04       Impact factor: 5.864

10.  Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats.

Authors:  Kenneth V Christensen; Henrik Leffers; William P Watson; Connie Sánchez; Pekka Kallunki; Jan Egebjerg
Journal:  BMC Neurosci       Date:  2010-01-27       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.